Phathom Pharmaceuticals Inc PHAT.OQ PHAT.O is expected to show a rise in quarterly revenue when it reports results on May 1 for the period ending March 31 2025
The Florham Park New Jersey-based company is expected to report a 1,417.6% increase in revenue to $29.016 million from $1.91 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Phathom Pharmaceuticals Inc is for a loss of $1.15 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 0.3% in the last three months.
Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $21.00, above its last closing price of $4.15.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -1.31 | -1.27 | -1.05 | Beat | 17.4 |
Sep. 30 2024 | -1.59 | -1.49 | -1.32 | Beat | 11.7 |
Jun. 30 2024 | -1.40 | -1.38 | -1.56 | Missed | -13 |
Mar. 31 2024 | -1.28 | -1.31 | -1.42 | Missed | -8.5 |
Dec. 31 2023 | -1.10 | -1.08 | -1.39 | Missed | -29.1 |
Sep. 30 2023 | -0.87 | -0.89 | -0.76 | Beat | 14.7 |
Jun. 30 2023 | -0.94 | -0.98 | -0.84 | Beat | 14.2 |
Mar. 31 2023 | -1.23 | -1.26 | -0.89 | Beat | 29.4 |
This summary was machine generated April 29 at 12:44 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。